Ultragenyx Sells Rare Disease Voucher for $210 Million

Ultragenyx Pharmaceutical agreed on Tuesday, October 6, 2026, to sell a Rare Pediatric Disease Priority Review Voucher for $210 million in cash, payable at closing, according to an 8-K filed with the SEC on October 7. The FDA awarded the voucher on Wednesday, August 19, 2026, when it approved GENGLYCOS, the gene therapy also known as DTX401, for glycogen storage disease type Ia in patients eight years and older.

The price is the highest of the 2026 voucher sales TradeFlock reviewed. The cash matters more than usual for Ultragenyx, which lost its lead late-stage readout in September and has said it will cut costs.

What the 8-K Says, and What It Leaves Out

The filing describes an asset purchase agreement with "the buyer" and never names it. The company press release on GlobeNewswire does not name the buyer either. Closing still depends on the Hart-Scott-Rodino waiting period expiring or being terminated. Ultragenyx said it will file the full agreement with its annual report for 2026.

Not all of the $210 million stays with Ultragenyx. The 8-K says that under a patent license agreement with the National Institutes of Health dated December 10, 2018, 20% of the gross proceeds will be paid to the NIH after closing. By TradeFlock's calculation, that is $42 million, which leaves about $168 million for Ultragenyx before transaction costs. No other licensor or partner share is disclosed for this voucher. The second quarter 10-Q does describe a separate voucher sharing right owed to former GeneTx unitholders, but that right is tied to the GeneTx acquisition, and the 8-K connects only the NIH to this sale. DTX401 came to Ultragenyx through its purchase of Dimension Therapeutics, and the filings we reviewed show no payment to Dimension's former holders from this voucher.

How $210 Million Compares With Recent Voucher Sales

Five other voucher sales TradeFlock found in 2026 were priced between $180 million and $205 million. Each figure below comes from a company release or SEC filing.

Seller	Date	Price	Source
Ultragenyx (GENGLYCOS)	Oct 6, 2026	$210 million	8-K
Cyprium Therapeutics (Fortress Biotech)	Feb 23, 2026	$205 million	Fortress release
Immedica	May 18, 2026	$200 million	Immedica release
Denali Therapeutics	Jun 18, 2026	$195 million	Denali release
Ascendis Pharma (closed)	Jun 17, 2026	$187.5 million	6-K
Rocket Pharmaceuticals	Apr 26, 2026	$180 million	8-K
Ultragenyx (Mepsevii) to Novartis	Dec 18, 2017	$130 million	Ultragenyx release
United Therapeutics to AbbVie	Aug 19, 2015	$350 million	8-K

At $210 million, Ultragenyx is $5 million above the Cyprium sale and $30 million above Rocket's $180 million from April. It also gets $80 million more than the $130 million Novartis paid Ultragenyx for its Mepsevii voucher in 2017. The record is still the $350 million AbbVie paid United Therapeutics in 2015, so this sale comes in $140 million below the top of the range. Cyprium makes a useful comparison because it also owes 20% of its proceeds to an NIH institute, according to Fortress's February release.

What the Cash Does for the Runway

Ultragenyx had $436 million in cash, cash equivalents and marketable securities on June 30, 2026, down from $737 million on December 31, 2025, according to its 10-Q, which shows $294 million of cash used in operating activities in the first half of 2026. Operations used $97 million in the second quarter alone, per the August 4 earnings release. The company said in the 10-Q that its capital would fund operations for at least the next 12 months.

By TradeFlock's calculation, the roughly $168 million Ultragenyx keeps after the NIH share covers about 1.7 quarters of operating cash use at the second quarter rate of $97 million. Adding that $168 million to the $436 million Ultragenyx held on June 30 gives about $604 million on a pro forma basis, also by TradeFlock's calculation. That figure does not subtract third quarter spending or transaction costs, and the cash arrives only at closing. In August, Ultragenyx reaffirmed 2026 revenue guidance of $730 million to $760 million, said combined R&D and SG&A would be flat to slightly down from 2025, and said it remained on a path to profitability in 2027.

That outlook has changed since then. On September 2, the company disclosed that the Phase 3 Aspire study of apazunersen in Angelman syndrome missed its primary endpoint, and said it would assess "significant expense reductions." In the release announcing the sale, CFO Howard Horn said the voucher "supports our path to profitability."

What Comes Next for Ultragenyx

There are three things to watch. The first is when HSR clears and the deal closes, because the money arrives only at closing. The second is whether the 10-K exhibit names the buyer. The third is a second voucher. Ultragenyx said on September 17 that it received another voucher with the FDA approval of FAYUVI (UX111) for Sanfilippo syndrome type A. The filings we reviewed do not say whether any partner shares in that one or whether it has been sold.

Rare disease companies have been raising money in several ways this year. Private equity has been buying specialty pharmacy assets, as in Warburg Pincus's deal for PANTHERx Rare, and venture investors have kept funding drug developers such as Enveda with its $311 million raise. Vouchers give approved rare disease drugmakers another option: cash that doesn't dilute shareholders, at prices now around $200 million.